A Drug with Two Prices
After 20 years, the monopoly for Abbvie’s Humira (adalimumab) has ended with the recent entry of Amgen’s biosimilar Amjevita. However, Amgen’s dual pricing strategy for its product has been raising some eyebrows.
- ‘The Price of Business’: A Major Fiscal Crisis is Brewing and Largely Ignored by the Media
- 1 big thing: Congress takes on PBMs
- Here comes Humira competition
- Humira Competitors Don’t Guarantee Lower Patient Drug Costs
- The State of Biosimilars: What to Watch
- ‘The Price of Business’: Discussing the Latest Inflation Report
- Alex Brill Interviewed on the Future of the Adalimumab Market
- Taking Stock of the Humira Biosimilars Market
- MGA’s Alex Brill on CNBC’s Squawk Box Discussing House Republican tax proposals
- Analyzing the Build It in America Act: Proposals for Business Tax Reform
